BeOne Medicines Ltd. growth

Reported trailing growth, forward expectations and three-year compound growth rates.

Trailing growth

Year over year

Revenue: +37.4%
EBITDA: +997.4%
EBIT: +331.9%
EPS: +1437.3%
Free cash flow: +452.0%
Operating cash flow: +506.3%

Forward estimates

Revenue: +14.9%
EBITDA: —
EPS: -86.0%

Three-year CAGR

Revenue: +55.7%
EBITDA: +270.7%
EBIT: +178.7%
Net income: +144.5%
EPS: +652.3%
Free cash flow: +240.6%

Latest available reported and market-derived figures. A dash means the source dataset does not currently cover that metric; it does not imply a zero value.